anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
LPLD is a rare autosomal recessive disorder, characterized by the presence of marked chylomicronemia and hence hypertriglyceridemia. Clinically the most severe manifestation of chylomicronemia, is acute pancreatitis, which can be lethal. There is no effective therapy available to modulate the course of the illness and prevent complications for these patients. The current clinical management consists of severe reduction of dietary fat that is hard if not almost impossible to comply with. LPLD subjects continue to experience pancreatitis attacks, and are admitted to intensive care units on several occasions.

Alipogene tiparvovec corrects or restores lipoprotein lipase (LPL) function long term, and hence reverses some symptoms, halts the disease progression and prevents further complications. Alipogene tiparvovec gene therapy ensures that a catabolically beneficial variant of the human LPL gene, LPL\[S447X\] is expressed and active in the relevant tissues in humans. Delivery of the gene is realized via intramuscular injection of an adeno-associated viral vector, pseudotyped with AAV1 capsids.
Low-grade inflammation is considered as a pathophysiological mechanism in a subtype of patients with major depressive disorder (MDD). Anti-inflammatory drugs have shown efficacy in treating MDD. However, it remains unclear how to identify suitable patients for anti-inflammatory treatment of depression. This study investigates the predictive value of pre-treatment high-sensitivity C-Reactive Protein (hsCRP) stratification on the outcome of celecoxib augmentation of vortioxetine. The PREDDICT study was conducted as a randomized, double-blind, placebo-controlled 6-week trial on augmentation of vortioxetine with celecoxib between December 2017 and April 2020 at the University of Adelaide (Australia). The present analysis focusses on the question of whether the pre-treatment hsCRP measurement and stratification of patients to depression with inflammation (hsCRP >3 mg/L) or without inflammation (hsCRP ≤3 mg/L) has an impact on the outcome of anti-inflammatory treatment with celecoxib. A total of n = 119 mostly treatment-resistant MDD patients with moderate to severe symptomatology were recruited in the trial. There was no effect of treatment group (celecoxib or placebo), pre-treatment hsCRP strata (with/without inflammation), or interaction between the two terms on treatment outcome. The results of the current analysis do not support the hypothesis that pre-treatment hsCRP level is predictive for response to anti-inflammatory treatment with celecoxib in MDD patients. Further research is needed to identify appropriate biomarkers for the prediction of anti-inflammatory treatment outcome in depression. CLINICAL TRIALS REGISTRATION: Australian New Zealand Clinical Trials Registry (ANZCTR), ACTRN12617000527369p. Registered on 11 April 2017, http://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12617000527369p.
PROBLEM TO BE SOLVED: To provide a dental composition capable of scarcely causing sticking of dirt even when used in the oral cavity for a long period and exhibiting deodorant and sterilizing effects without causing decomposition or deterioration of strength of a resin even when undergoing light irradiation, a method for relatively simply cleaning a dental material and a denture cleaner. SOLUTION: This dental composition is obtained by mixing titanium dioxide as a photocatalyst component and silica or alumina as a component for preventing the resin deterioration in a dental resin composing the dental composition used in the oral cavity. In the process, the surface of the titanium dioxide is preferably coated with the silica or alumina. The surface coating ratio of the titanium oxide is preferably 0.01-25% and 0.001-10 pts.wt. of the surface- coated titanium dioxide is preferably mixed in 100 pts.wt. of the dental resin. The method for cleaning comprises dipping the dental material subjected to cleaning in a dispersion of the titanium dioxide or coating the dental material with the solution and then carrying out light irradiation.
Women seeking ANC services at 2 public health centers in Lilongwe, Malawi will be enrolled into this study arm during study recruitment. Individuals enrolled in this arm will be administered the Enhanced Friendship Bench intervention from date of enrollment through 6 months post-partum.
Chronic kidney disease (CKD) is a complication of diabetes that affects circulating drug concentrations and elimination of drugs from the body. Multiple drugs may be prescribed for treatment of diabetes and co-morbidities, and CKD complicates the pharmacotherapy selection and dosing regimen. Characterizing variations in renal drug clearance using models requires large clinical datasets that are costly and time-consuming to collect. We propose a flexible approach to incorporate impaired renal clearance in pharmacokinetic (PK) models using descriptive statistics and secondary data with mechanistic models and PK first principles. Probability density functions were generated for various drug clearance mechanisms based on the degree of renal impairment and used to estimate the total clearance starting from glomerular filtration for metformin (MET) and dapagliflozin (DAPA). These estimates were integrated with PK models of MET and DAPA for simulations. MET renal clearance decreased proportionally with a reduction in estimated glomerular filtration rate (eGFR) and estimated net tubular transport rates. DAPA total clearance varied little with renal impairment and decreased proportionally to reported non-renal clearance rates. Net tubular transport rates were negative to partially account for low renal clearance compared with eGFR. The estimated clearance values and trends were consistent with MET and DAPA PK characteristics in the literature. Dose adjustment based on reduced clearance levels estimated correspondingly lower doses for MET and DAPA while maintaining desired dose exposure. Estimation of drug clearance rates using descriptive statistics and secondary data with mechanistic models and PK first principles improves modeling of CKD in diabetes and can guide treatment selection.
This intervention is based on established clinical practice guidelines for prevention and treatment of hypertension (HTN), which recommends weight loss (if overweight), limiting sodium and alcohol intake, regular physical activity, reducing alcohol intake, and eating a low-fat diet that is rich in fruit and vegetables. MINT-TLC will be conducted by trained research personnel. Patients will attend 10 classes over 12 weeks (intensive phase) followed by individual monthly MINT sessions for 3 months (maintenance phase). We chose the intervention schedules to pattern after the methodology of therapeutic lifestyle interventions with proven efficacy in hypertensive patients, specifically, Trial of Nonpharmacologic Approaches in Elderly Hypertensives (TONE) and PREMIER trials.
The invention belongs to the field of daily chemicals, and provides a preparation method of toothpaste rich in tea amino acid. The method comprises the following steps: 1) micronizing fresh green tea to obtain tea powder, and sieving to obtain tea powder with particle size of 10-50 μm. 2) Ultrasonic cold extraction: adding the superfine powder into 55% ethanol extract at 5-15 deg.C, wherein the weight ratio of tea powder to extract is 1:5-1: 100. Shaking in ultrasonic oscillator for 1-180min, adjusting pH to 7-8 with sodium hydroxide, and filtering. 3) And (3) re-purification: filtering the fine filtrate with active carbon; filtering the obtained filtrate with 0.35-0.45um water phase filtering membrane to obtain folium Camelliae sinensis extract. 4) Preparing tea amino acid toothpaste: the tea extract is matched with common toothpaste raw materials to prepare the toothpaste rich in tea amino acid. The toothpaste has the effects of natural nutrition, mild care, effective prevention of decayed teeth, breath freshening and the like.
FIELD: medicine, as antagonist of receptor of serotonine-2. SUBSTANCE: diaryl alkanes have formula I   where R 1  is aryl, R 2  is H, R 3  is -BNR 4 R 5 , group where R 4  and R 5  is H, alkyl, or R 4  and R 5  together with nitrogen atom which with they are bound represent heterocyclic group comprising 3-6 ring atom and B is alkylene C 2 -C 6  group or -D-R 7  group where D is single carbon-carbon bond or alkylene group, A is C 2 -C 8  alkylene group. Compound having formula II   is used as reagent 1. Compound having formula Z-B-NR 4 R 5  where Z is OH group or group enables splitting, B, R 4  and R 5  are as it mentioned above is used as reagent 2. Compound or its pharmaceutically acceptable salts may be used in medicine. EFFECT: improved quality.
During the manufacture of a non-spherical seamless capsule, at first the filling material is covered by a film and the so formed seamless capsule C1 is used in a drying device 12 to be dried until the solution-medium-containing rate of the film becomes a given value. Then said seamless capsule is heated by a heating device 38 and the film will be in a semi-sol state. In addition, the heated seamless capsule is formed to become a given non-spherical shape by the use of a shape-processing device 52 constructed from the shrinkage-shape-processing device etc. Thus the film of the dried spherical seamless capsule is used in a semi-sol state, so its elasticity is low and the stress relaxation time also becomes short, and the shape-processing can be performed in a short time, the original spherical shape will not be recovered. Furthermore, because the alteration of the material property in a semi-sol state is small, the temperature management is also easy. After being processed into a non-spherical shape, the drying process is not necessary or its necessity is small, then the wrinkles on the surface of the film is difficult to occur and the unevenness of the shape is also small.
UVA1 irradiaton up to 5 times per week, for up to 16 weeks using German manufactured UVA1 emitting light system. UVA1 dose will be applied with up to 130 J/cm2.
Epithelial ovarian cancer (OC) is the deadliest female reproductive cancer; an estimated 13,270 women will die from OC in 2023. Platinum-based chemotherapy resistance mechanisms contribute to poor OC 5-year survival rates. Peripheral inflammation is linked to various disease states and we previously identified unique peritoneal microbial features predictive of OC. We hypothesized that unique peripheral immune profiles and peritoneal microbial features may be predictive of disease-free interval (time to recurrence) and response to chemotherapy in participants with OC. We also investigated self-rated health (SRH) scores in the context of peripheral inflammation as a potential screening tool for OC. Blood and peritoneal fluid were collected from participants with OC or a benign adnexal mass (BPM). Lymphocyte populations were analyzed using Fluorescence Activated Cell Sorting, serum cytokine levels were analyzed using the Human Th17 Magnetic Bead Panel assay and peritoneal fluid microbial features were analyzed using Next Generation Sequencing (NGS). Participants completed a standardized questionnaire on self-rated physical and emotional health. Participants were classified into three chemotherapy response categories: platinum-refractory, platinum-resistant or platinum-sensitive. A significant positive correlation was found between elevated inflammatory status on the day of surgery and longer disease-free interval. SRH measures did not correlate with immune status in participants with OC or a BPM. We identified a correlation between peritoneal microbial features and chemotherapy response. We conclude that immune dysbiosis may be useful in predicting OC recurrence. The immune findings reported here set the framework for additional studies utilizing immune profiles to predict platinum-based chemotherapy responsiveness in OC.
BACKGROUND: Acute appendicitis (AA) is one of the most common reasons for visiting the emergency room. The lack of proper diagnosis and rapid treatment of AA may lead to severe complications such as intestinal perforation and increased mortality. This study aimed to evaluate the diagnostic accuracy of the Alvarado criteria, ultrasound, and CRP criteria in comparison with their combined use in patients with suspected AA who presented to the emergency room.
METHODS: In this diagnostic accuracy study, 1411 patients with suspected AA who presented to the emergency department of Firoozabadi Hospital affiliated with Iran University of Medical Sciences and underwent appendectomy from October 2019 to October 2021 were examined. Nine hundred eighty-eight patients were enrolled. All patients were assessed using Alvarado, CRP, and ultrasound. The definitive diagnosis of AA was based on pathological findings and was considered the gold standard. Statistical analyses were performed with STATA VER 11.5. The diagnostic accuracy for each group was compared using the Pearson chi-square test. A value of p < 0.05 was considered statistically significant.
RESULTS: The mean age was 29.57 ± 13.66 years. The sensitivity and specificity of Alvarado in the diagnostic accuracy of appendicectomy were 75.2% and 61.3% (CI = 95%), respectively. The sensitivity of ultrasound and CRP for predicting appendicitis was significantly higher than the Alvarado criteria. The diagnostic accuracy for CRP was significantly higher than ultrasound (64.9% vs. 60.7%, P: 0.003). The diagnostic accuracy of the simultaneous use of Alvarado + CRP and CRP + Ultrasound was significantly higher than that of Alvarado + ultrasound. The sensitivity, specificity, and diagnostic accuracy of the simultaneous use of all three criteria together (Alvarado + Ultrasound + CRP) were estimated to be 94.9%, 25.8%, and 81.5% (CI = 95%), respectively, which were significantly higher than the use of other criteria.
CONCLUSION: This study showed that the Alvarado criteria had inadequate diagnostic sensitivity and accuracy for diagnosing acute appendicitis. The diagnostic accuracy of acute appendicitis increases to over 90% using the three Alvarado, ultrasound, and CRP criteria at the same time.
Subjects with recurrent epithelial ovarian carcinoma or recurrent primary peritoneal cancer, for whom autologous tumor or malignant effusion has been harvested and is available for lysate preparation, are eligible, provided all other eligibility criteria are fulfilled. Harvested tumor or malignant effusion will be shipped to Cognate BioServices (Sunnyvale, CA) for preparation of lysate. If sufficient amount of lysate for vaccine can be generated, subjects will be enrolled to the study.

Subjects will undergo apheresis on day -35 to -29 to harvest peripheral blood mononuclear cells (PBMC). The apheresis product will be shipped to Cognate BioServices, where DC will be prepared and pulsed with autologous lysate according to proprietary technology. Following apheresis, subjects will receive two cycles of biological antiangiogenesis/immunomodulatory therapy comprising intravenous bevacizumab at 10 mg/kg on day -28 and -14, which may be followed by 7 days of oral metronomic cyclophosphamide at 50 mg daily (days -28 to -21, and -14 to -7, respectively). Subjects will receive three doses of intradermal vaccination with \~5-10 x 106 dendritic cells (DCVax-L) on days 0, 14 and 28. Subjects will also receive intravenous bevacizumab at 10 mg/kg concurrently with intradermal DCVax-L on day 0 and 14, which may be followed by oral cyclophosphamide at 50 mg for 7 days (days 0 to 7, and 14 to 21, respectively). The last DCVax-L (day 28) may be followed by oral cyclophosphamide at 50 mg daily x 7 days (days 28 to 35), but no bevacizumab will be given on day 28. Prevnar, an FDA approved seven-valent vaccine against Pneumococcus pneumoniae, will be given intramuscularly on day 0 as positive control of immune responsiveness. Two weeks following third vaccine dose (day 42), patients will undergo immune assessment.

Subjects will be contacted every 6 months for 5 years and then annually for survival. Subject will have the option of enrolling in other combinatorial immunotherapy trials when these are available, if they satisfy enrollment criteria. Subjects will have the option of continuing vaccination every two months till exhaustion of DCVax-L or disease progression, whichever occurs first.
INTRODUCTION: Despite international efforts, the number of individuals struggling with obesity is still increasing. An important aspect of obesity prevention relates to identifying individuals at risk at early stage, allowing for timely risk stratification and initiation of countermeasures. However, obesity is complex and multifactorial by nature, and one isolated (bio)marker is unlikely to enable an optimal risk stratification and prognosis for the individual; rather, a combined set is required. Such a multicomponent interpretation would integrate biomarkers from various domains, such as classical markers (eg, anthropometrics, blood lipids), multiomics (eg, genetics, proteomics, metabolomics), lifestyle and behavioural attributes (eg, diet, physical activity, sleep patterns), psychological traits (mental health status such as depression) and additional host factors (eg, gut microbiota diversity), also by means of advanced interpretation tools such as machine learning. In this paper, we will present a protocol that will be employed for a scoping review that attempts to summarise and map the state-of-the-art in the area of multicomponent (bio)markers related to obesity, focusing on the usability and effectiveness of such biomarkers.
METHODS AND ANALYSIS: PubMed, Scopus, CINAHL and Embase databases will be searched using predefined key terms to identify peer-reviewed articles published in English until January 2024. Once downloaded into EndNote for deduplication, CADIMA will be employed to review and select abstracts and full-text articles in a two-step procedure, by two independent reviewers. Data extraction will then be carried out by several independent reviewers. Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews and Peer Review of Electronic Search Strategies guidelines will be followed. Combinations employing at least two biomarkers from different domains will be mapped and discussed.
ETHICS AND DISSEMINATION: Ethical approval is not required; data will rely on published articles. Findings will be published open access in an international peer-reviewed journal. This review will allow guiding future directions for research and public health strategies on obesity prevention, paving the way towards multicomponent interventions.
PURPOSE:To obtain the subject composition excellent in stability with the lapse of time for its active ingredient, containing an arylpropionic acid-based nonsteroidal anti-inflammatory agent and packed in a container having synthetic resin inner surface. CONSTITUTION:This dentifrice composition is obtained by formulating 0.01-5wt.% of an arylpropionic acid-based nonsteroidal antiinflammatory agent as active ingredient in a base blended with 0.05-5wt.% of at least one kind of compound selected from propylene glycol fatty acid esters, glycerin fatty acid esters and higher alcohol fatty acid esters and 0.01-10wt.% of a nonionic surfactant (e.g. polyoxyethylene sorbitan monooleate). This composition is prepared by packing in a container with at least the innermost layer representing a synthetic resin (e.g. a laminated tube). This composition, which can have anti-infl-ammatory activity and alveolar bone resorption-suppressive activity over a long period, is useful for treating and/or preventing periodontosis such as gingivitis and periodontitis. The above-mentioned anti-inflammatory agent is e.g. ibuprofen, flurbiprofen.
<P>PROBLEM TO BE SOLVED: To provide an orally-administerable eliminator of Heterobothrium okamoto parasitic on fishes and a method of the elimination.  <P>SOLUTION: The Heterobothrium okamoto eliminator works for fishes and includes bithionol as an active ingredient. It is particularly effective against Heterobothrium okamoto parasitic on Percomorphi fishes. The method of the Heterobothrium okamoto elimination comprises orally administering bithionol in an amount of 10-250 mg/kg body weight/day. The method of the Heterobothrium okamoto elimination includes orally administering bithionol for 1-3 days, or every other day.  <P>COPYRIGHT: (C)2010,JPO&INPIT
BACKGROUND: Regardless of progress in treatment of coronary artery disease (CAD), there is still a significant residual risk of death in patients with CAD, highlighting the need for additional risk stratification markers. Our previous study provided evidence for a novel blood pressure-regulating mechanism involving 4β-hydroxycholesterol (4βHC), an agonist for liver X receptors, as a hypotensive factor. The aim was to determine the role of 4βHC as a prognostic factor in CAD.
METHODS AND RESULTS: The ARTEMIS (Innovation to Reduce Cardiovascular Complications of Diabetes at the Intersection) cohort consists of 1946 patients with CAD. Men and women were analyzed separately in quartiles according to plasma 4βHC. Basic characteristics, medications, ECG, and echocardiography parameters as well as mortality rate were analyzed. At baseline, subjects with a beneficial cardiovascular profile, as assessed with traditional markers such as body mass index, exercise capacity, prevalence of diabetes, and use of antihypertensives, had the highest plasma 4βHC concentrations. However, in men, high plasma 4βHC was associated with all-cause death, cardiac death, and especially sudden cardiac death (SCD) in a median follow-up of 8.8 years. Univariate and comprehensively adjusted hazard ratios for SCD in the highest quartile were 3.76 (95% CI, 1.6-8.7; P=0.002) and 4.18 (95% CI, 1.5-11.4; P=0.005), respectively. In contrast, the association of cardiac death and SCD in women showed the lowest risk in the highest 4βHC quartile.
CONCLUSIONS: High plasma 4βHC concentration was associated with death and especially SCD in men, while an inverse association was detected in women. Our results suggest 4βHC as a novel sex-specific risk marker of cardiac death and especially SCD in chronic CAD.
REGISTRATION INFORMATION: clinicaltrials.gov. Identifier NCT01426685.
A management system for dispensing and prescribing medicine has a server 1, a first detected element 7, a second detected element 14, a detection means, and a personal digital assistant 5. The server has a memory means 2 to associate and memorize prescription data, patient data, and dispensing and prescribing medicine schedule data of each other, and a control means 3 to output an information signal based on dispensing and prescribing medicine schedule. The first detected element 7 is provided for limiting the patient. The second detected element 14 is provided for limiting the medicine which is prescribed. The detection means detects the both detected elements. The personal digital assistant 5 outputs the information signal based on the information signal from a server 1, detects the each detected element 7, 14 by the detection means, and judges whether the medicine which is prescribed is appropriate for the patient or not by sending to and receiving from the server 1.